{"gene":"KCNJ11","run_date":"2026-06-10T02:59:49","timeline":{"discoveries":[{"year":1997,"finding":"Kir6.2 is the primary subunit of the K(ATP) channel at which ATP acts to mediate channel inhibition; truncation of the C-terminus of Kir6.2 (ΔC26) produces ATP-sensitive K+ channels in the absence of SUR1, demonstrating the ATP-inhibitory site resides on Kir6.2. SUR1 is required for sensitivity to sulfonylureas, diazoxide, and activation by Mg-ADP.","method":"Truncation mutagenesis of Kir6.2 expressed in Xenopus oocytes; electrophysiology (patch-clamp)","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstitution with mutagenesis in Xenopus oocyte expression system; foundational result widely replicated","pmids":["9144288"],"is_preprint":false},{"year":1996,"finding":"Kir6.2 co-expression with SUR1 reconstitutes the beta-cell K(ATP) channel; a homozygous L147P mutation in Kir6.2 (disrupting the M2 transmembrane domain) causes familial persistent hyperinsulinemic hypoglycemia of infancy (PHHI), demonstrating Kir6.2 is a necessary subunit for normal regulated insulin release.","method":"Genetic sequencing, functional reconstitution by coexpression of Kir6.2 and SUR1","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — disease-causing mutation identified with functional reconstitution context, independently replicated across populations","pmids":["8923010"],"is_preprint":false},{"year":1996,"finding":"A novel SUR isoform (SUR2B) co-expressed with Kir6.2 reconstitutes smooth muscle-type K(ATP) channels that are activated by diazoxide and pinacidil, establishing that tissue-specific K(ATP) channel phenotypes arise from combinatorial assembly of Kir6.2 with different SUR isoforms.","method":"Heterologous coexpression in mammalian cell line; patch-clamp electrophysiology","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstitution experiment with functional readout, replicated by multiple groups","pmids":["8798681"],"is_preprint":false},{"year":1999,"finding":"The N-terminus of Kir6.2 is involved in coupling sulfonylurea binding at SUR1 to closure of the Kir6.2 pore; N-terminal deletions (ΔN5, ΔN9, ΔN14) increase open probability, reduce ATP sensitivity, and abolish high-affinity tolbutamide block when co-expressed with SUR1, but do not alter intrinsic Kir6.2 gating in the absence of SUR1.","method":"N-terminal deletion and site-directed mutagenesis of Kir6.2; patch-clamp in Xenopus oocytes","journal":"The Journal of physiology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — mutagenesis with rigorous electrophysiological controls, single lab but multiple deletion constructs","pmids":["10381582"],"is_preprint":false},{"year":1999,"finding":"The R50 residue in the N-terminus of Kir6.2 is important for ATP inhibition; R50S/A/G mutations substantially reduce ATP sensitivity (Ki increased from 117 µM to 800 µM–3.8 mM). Combining N-terminal (R50S) and C-terminal (E179Q) mutations has additive effects, suggesting N- and C-termini cooperate to mediate channel closure by ATP.","method":"Site-directed mutagenesis; patch-clamp of excised membrane patches from Xenopus oocytes","journal":"The Journal of physiology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — systematic mutagenesis with quantitative functional readouts, single lab","pmids":["9831713"],"is_preprint":false},{"year":1999,"finding":"PKA directly phosphorylates Kir6.2 at Ser372 in the C-terminus and SUR1 at Ser1571; phosphorylation of Kir6.2 at Ser372 increases channel activity, while phosphorylation of SUR1 modulates basal channel properties (burst duration, interburst interval, open probability) and surface expression. PKA stimulation via Gs-coupled receptors can phosphorylate Kir6.2 in intact cells.","method":"Site-directed mutagenesis of PKA consensus sequences; phosphorylation assays in Xenopus oocyte homogenates and intact cells; electrophysiology","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct phosphorylation assay combined with mutagenesis and electrophysiology, single lab with multiple orthogonal methods","pmids":["10469651"],"is_preprint":false},{"year":1999,"finding":"Kir6.2 physically associates with SUR2A to form the cardiac K(ATP) channel; co-immunoprecipitation of in vitro-translated proteins demonstrated direct physical interaction. The proximal C-terminus and M2 transmembrane domain of Kir6.2 are required for assembly with SUR2A, while the distal 37 amino acids of the C-terminus are not.","method":"Co-immunoprecipitation of in vitro-translated Kir6.2 deletion mutants with SUR2A","journal":"Journal of molecular and cellular cardiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP with deletion mapping, single lab, in vitro translated proteins","pmids":["10093054"],"is_preprint":false},{"year":2001,"finding":"Kir6.2 is the pore-forming subunit mediating sarcolemmal K(ATP) channel activity in ventricular cardiomyocytes; Kir6.2-knockout mice lack electrophysiological and contractile responses to K+ channel openers (pinacidil, P-1075) in the heart. In contrast, Kir6.2 plays no role in arterial smooth muscle K(ATP) channels, where only Kir6.1 is expressed.","method":"Genetic knockout (Kir6.2-KO mice); patch-clamp electrophysiology; gene transfer rescue experiment; contractile function assays","journal":"Circulation research","confidence":"High","confidence_rationale":"Tier 2 / Strong — knockout mice combined with gene transfer rescue and multiple functional readouts","pmids":["11282890"],"is_preprint":false},{"year":2000,"finding":"In pancreatic beta-cells, Kir6.2 subunits form the K+ ion-permeable pore and primarily confer ATP inhibition; dominant-negative Kir6.2-G132S expression and Kir6.2 knockout mice establish that K(ATP) channels are the major determinant of beta-cell resting membrane potential, are required for both glucose- and sulfonylurea-induced membrane depolarization, Ca2+ entry, and insulin secretion, and are important for beta-cell survival and islet architecture.","method":"Transgenic dominant-negative mice (Kir6.2-G132S); Kir6.2 knockout mice; insulin secretion assays; electrophysiology; calcium imaging","journal":"Diabetes","confidence":"High","confidence_rationale":"Tier 2 / Strong — two independent genetic models with multiple orthogonal phenotypic readouts","pmids":["10868950"],"is_preprint":false},{"year":2002,"finding":"The C-terminus of Kir6.2 associates with lipid membranes via a conserved domain; systematic mutagenesis of D307–F315 identifies residues E308, I309, W311, and F315 on one face of a conserved alpha-helix as critical determinants of phospholipid (PIP2) interaction and K(ATP) channel activity.","method":"GFP-tagged fragment membrane association assay; site-directed mutagenesis; patch-clamp electrophysiology","journal":"The Journal of general physiology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — mutagenesis combined with membrane association assay and electrophysiology, single lab","pmids":["12034765"],"is_preprint":false},{"year":2003,"finding":"Positively charged residues K185 and R201 in the C-terminus of Kir6.2 are critical for channel inhibition by adenine nucleotides via electrostatic interaction with phosphate groups; R201 interacts with the alpha-phosphate to stabilize a closed state, while K185 interacts with the beta-phosphate in a state-independent manner. R192 (C-terminus) and R50 (N-terminus) also contribute to ATP sensitivity.","method":"Site-directed mutagenesis; patch-clamp of Xenopus oocytes","journal":"Biophysical journal","confidence":"High","confidence_rationale":"Tier 1 / Moderate — systematic mutagenesis of multiple residues with quantitative electrophysiological readouts, single lab","pmids":["12524280"],"is_preprint":false},{"year":2003,"finding":"Kir6.2 knockout abolishes ischemic preconditioning-induced protection of myocardial bioenergetics; preconditioned wild-type hearts showed significantly higher ATP turnover, synthesis rate, and creatine kinase-catalyzed phosphotransfer than Kir6.2-KO hearts, demonstrating that sarcolemmal K(ATP) channels (via Kir6.2) are integral to ischemic preconditioning-induced cardiac energetic protection.","method":"Kir6.2 knockout mice; 18O-assisted 31P-NMR spectroscopy; ischemia-reperfusion protocol","journal":"American journal of physiology. Heart and circulatory physiology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — knockout with quantitative metabolic measurements, single lab","pmids":["12598229"],"is_preprint":false},{"year":2004,"finding":"Heterozygous activating (gain-of-function) missense mutations in KCNJ11 (Kir6.2) cause permanent neonatal diabetes by reducing ATP-inhibitory sensitivity of K(ATP) channels; the most common mutation (R201H) when co-expressed with SUR1 in Xenopus oocytes greatly reduced the ability of ATP to block mutant channels, hyperpolarizing beta-cells and preventing insulin secretion. Some mutations also cause DEND syndrome (developmental delay, epilepsy, neonatal diabetes).","method":"KCNJ11 sequencing; heterologous expression of mutant Kir6.2/SUR1 in Xenopus oocytes; patch-clamp electrophysiology; in vivo insulin secretion tests","journal":"The New England journal of medicine","confidence":"High","confidence_rationale":"Tier 1 / Strong — functional reconstitution with mutagenesis replicated across multiple mutations and labs","pmids":["15115830"],"is_preprint":false},{"year":2004,"finding":"Neonatal diabetes mutations in Kir6.2 reduce ATP inhibition by two distinct mechanisms: mutations causing diabetes alone (e.g., R201C) directly impair ATP binding/transduction, while mutations causing severe DEND syndrome (e.g., Q52R, V59G) act indirectly by biasing the channel toward the open state. Disease severity correlates with the magnitude of reduction in ATP sensitivity. The slide helix (V59) is implicated in Kir channel gating.","method":"Site-directed mutagenesis; heterologous expression in Xenopus oocytes; patch-clamp electrophysiology with kinetic analysis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstitution with mutagenesis and mechanistic dissection, replicated across multiple mutations","pmids":["15583126"],"is_preprint":false},{"year":2005,"finding":"The I296L mutation at the internal mouth of the Kir6.2 pore (DEND syndrome) increases whole-cell K(ATP) currents by stabilizing the open state of the channel and possibly reducing ATP binding via allosteric effects; kinetic analysis revealed the mutation impairs ATP sensitivity indirectly, implicating this region in Kir-channel gating.","method":"Site-directed mutagenesis; expression in Xenopus oocytes; patch-clamp electrophysiology; kinetic analysis","journal":"EMBO reports","confidence":"High","confidence_rationale":"Tier 1 / Moderate — mutagenesis with detailed kinetic analysis, single lab","pmids":["15864298"],"is_preprint":false},{"year":2005,"finding":"Neonatal diabetes mutations Y330C and F333I in Kir6.2 reduce ATP inhibition and alter Kir6.2/SUR1 interactions; Y330C impairs ATP binding directly and stabilizes the open state; F333I alters ATP binding/transduction directly and dramatically enhances stimulatory MgATP effects mediated via SUR1. At least three SUR1 subunits must bind/hydrolyse MgATP to open F333I mutant channels.","method":"Site-directed mutagenesis; heterologous expression in Xenopus oocytes; patch-clamp electrophysiology","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1 / Moderate — mutagenesis with mechanistic dissection of subunit interactions, single lab","pmids":["15962003"],"is_preprint":false},{"year":2005,"finding":"High-affinity repaglinide binding requires both SUR1 and Kir6.2; repaglinide binds with ~150-fold higher affinity to SUR1 co-expressed with Kir6.2 compared to SUR1 alone. N-terminal deletion of Kir6.2 (ΔN14) abolishes this affinity enhancement, indicating the Kir6.2 N-terminus is required for high-affinity repaglinide binding and functional inhibition. Glibenclamide binding affinity depends primarily on SUR1.","method":"Radioligand binding assay ([3H]repaglinide, [3H]glibenclamide); N-terminal deletion of Kir6.2; patch-clamp electrophysiology","journal":"British journal of pharmacology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — binding assay with mutagenesis and electrophysiology, single lab with multiple orthogonal methods","pmids":["15678092"],"is_preprint":false},{"year":2006,"finding":"Six novel Kir6.2 mutations (H46Y, N48D, E227K, E229K, E292G, V252A) causing neonatal diabetes all reduce K(ATP) channel inhibition by MgATP; E227K and E229K enhance intrinsic open probability (indirectly reducing ATP sensitivity), while H46Y, N48D, E292G, and V252A likely affect ATP binding directly, as they lie near the predicted ATP-binding site. None substantially altered tolbutamide sensitivity.","method":"Heterologous expression of mutant Kir6.2/SUR1 in Xenopus oocytes; patch-clamp electrophysiology","journal":"Pflugers Archiv : European journal of physiology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — functional reconstitution with mutagenesis, single lab","pmids":["17021801"],"is_preprint":false},{"year":2006,"finding":"Induction of the R201H Kir6.2 mutation in INS-1 beta-cells strongly reduces K(ATP) channel ATP sensitivity (IC50 from ~20 µM to ~2 mM), prevents metabolic substrate-induced channel closure, abolishes electrical activity and insulin secretion, directly demonstrating that Kir6.2 gain-of-function mutations cause neonatal diabetes by hyperpolarizing beta-cells.","method":"Stable tetracycline-regulated expression in INS-1 cells; patch-clamp electrophysiology; insulin secretion assay","journal":"Diabetes","confidence":"High","confidence_rationale":"Tier 1 / Moderate — inducible expression system with electrophysiology and secretion assays in beta-cell line, single lab","pmids":["17065345"],"is_preprint":false},{"year":2007,"finding":"The G53D Kir6.2 mutation reduces channel ATP sensitivity, causing intermediate DEND syndrome; G53D channels co-expressed with SUR1 (pancreatic/neuronal isoform) show high-affinity block by gliclazide, but G53D channels with SUR2A (skeletal muscle isoform) are insensitive to gliclazide while remaining sensitive to glibenclamide, explaining why glibenclamide but not gliclazide improved motor function in a DEND patient.","method":"Reconstitution of mutant Kir6.2/SUR1 or Kir6.2/SUR2A in Xenopus oocytes; patch-clamp electrophysiology; clinical treatment assessment","journal":"The Journal of clinical endocrinology and metabolism","confidence":"High","confidence_rationale":"Tier 1 / Moderate — reconstitution with two SUR isoforms plus clinical correlation, single lab","pmids":["18073297"],"is_preprint":false},{"year":2007,"finding":"PIP2 binds to Kir6.2 at a site involving residues K39, N41, R54 (N-terminus), K67 (transmembrane domain), and R176, R177, E179, R301 (C-terminus), identified by homology modelling and validated by mutagenesis; PIP2 increases channel opening and decreases ATP binding and channel inhibition.","method":"Homology modelling; ligand docking; site-directed mutagenesis; patch-clamp electrophysiology in Xenopus oocytes","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1 / Moderate — computational model validated by systematic mutagenesis and electrophysiology, single lab","pmids":["17673911"],"is_preprint":false},{"year":2009,"finding":"Residues 28–32 in the N-terminus of Kir6.2 physically and functionally interact with SUR1 (specifically residues 196–288 of SUR1); an in-frame deletion of residues 28–32 impairs coupling between SUR1 and Kir6.2, increases intrinsic open probability, reduces ATP sensitivity, and disrupts co-immunoprecipitation with SUR1 N-terminal fragments.","method":"Co-immunoprecipitation; heterologous expression in Xenopus oocytes; patch-clamp electrophysiology","journal":"The Journal of clinical endocrinology and metabolism","confidence":"High","confidence_rationale":"Tier 2 / Moderate — co-IP combined with electrophysiology and mutagenesis, single lab with two orthogonal methods","pmids":["19351728"],"is_preprint":false},{"year":2010,"finding":"Ankyrin-B directly associates with Kir6.2 in the cardiac sarcolemma; primary cardiomyocytes lacking ankyrin-B display defects in Kir6.2 protein expression, membrane expression, and K(ATP) channel function, as well as altered channel gating. Ankyrin-B forms a membrane complex with K(ATP) channels and the Na/K-ATPase.","method":"Co-immunoprecipitation; Western blot; patch-clamp electrophysiology in ankyrin-B deficient primary myocytes; subcellular fractionation","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal co-IP with functional KO phenotype and multiple readouts, single lab","pmids":["20610380"],"is_preprint":false},{"year":2011,"finding":"A Ca2+-dependent PKC inhibits Kir6.2/SUR2B channel complexes by promoting internalization; Ser372 in the distal C-terminus of Kir6.2 is the critical phosphorylation site for this inhibitory effect, distinct from the activating PKA phosphorylation of the same residue.","method":"Site-directed mutagenesis (Ser372); biochemical internalization assay; patch-clamp electrophysiology; PKC activator/inhibitor pharmacology","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mutagenesis plus electrophysiology and biochemistry, single lab","pmids":["22207763"],"is_preprint":false},{"year":2012,"finding":"A molecular interaction between SUR1-E203 and Kir6.2-Q52 regulates K(ATP) channel ATP sensitivity; E203K in SUR1 combined with Q52E in Kir6.2 increases ATP sensitivity ~100-fold over wild-type. Cross-linking of E203C (SUR1) and Q52C (Kir6.2) locks the channel in a closed state reversible by reducing agents, demonstrating close proximity and a functionally critical SUR1–Kir6.2 interface.","method":"Site-directed mutagenesis; disulfide cross-linking; patch-clamp electrophysiology in Xenopus oocytes","journal":"The Journal of general physiology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — chemical cross-linking plus mutagenesis with quantitative electrophysiology, single lab with orthogonal methods","pmids":["22802363"],"is_preprint":false},{"year":2013,"finding":"βIV-spectrin serves as a scaffold that targets CaMKII to pancreatic islet beta-cells; CaMKII directly phosphorylates Kir6.2 at Thr224, inhibiting K(ATP) channel function and consistent with aberrant insulin regulation. βIV-spectrin mutant mice lacking CaMKII-binding motifs show selective loss of CaMKIIδ and aberrant Kir6.2 phosphorylation.","method":"Co-immunoprecipitation; site-directed mutagenesis (T224); patch-clamp electrophysiology; transgenic mice; in vitro kinase assay","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro kinase assay with mutagenesis, electrophysiology, and in vivo transgenic validation, single lab with multiple orthogonal methods","pmids":["24101510"],"is_preprint":false},{"year":2005,"finding":"Kir6.2 channel protein is degraded via the ubiquitin-proteasome pathway; Kir6.2 has a short half-life (~1.9 h) in COS cells. Proteasome inhibitors (MG132, ALLN, lactacystin) prolong Kir6.2 half-life and increase ubiquitinated Kir6.2, augmenting K(ATP) currents. The Na+ channel blocker aprindine inhibits 20S proteasome activity and similarly stabilizes Kir6.2.","method":"Pulse-chase/half-life analysis; proteasome inhibitors; ubiquitination assay; patch-clamp electrophysiology in COS cells and neonatal cardiomyocytes","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple proteasome inhibitors with ubiquitination assay and electrophysiology, single lab","pmids":["15882977"],"is_preprint":false},{"year":2006,"finding":"Targeted expression of Kir6.2 in mitochondria increases mitochondrial K+ influx, confers protection against hypoxic stress, and attenuates mitochondrial Ca2+ accumulation; an inactive Kir6.2 mutant abolishes this protection, demonstrating that K+ conductance through Kir6.2 in the inner mitochondrial membrane directly protects against hypoxic injury.","method":"Mitochondria-targeted Kir6.2 expression (pCMV/mito/GFP vector); colocalization studies; K+-sensitive fluorescent dye (PBFI AM); mitochondrial Ca2+ imaging (rhod-2); LDH release assay","journal":"The Journal of physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — targeted expression with inactive mutant control and multiple functional readouts, single lab","pmids":["16959852"],"is_preprint":false},{"year":2014,"finding":"Kir6.2-containing K(ATP) channels mediate the cardioprotective effects of resveratrol; resveratrol enhances AMPK phosphorylation and promotes physical association of AMPK with Kir6.2. Kir6.2 knockout abolishes cardioprotection by resveratrol in vivo and in vitro. AMPK activator cardioprotection is also lost in Kir6.2 KO, placing Kir6.2 downstream of AMPK in the cardioprotective signaling pathway.","method":"Kir6.2 knockout mice; ischemia/reperfusion injury; co-immunoprecipitation (AMPK–Kir6.2); infarct size measurement; neonatal cardiomyocyte assays","journal":"Cardiovascular diabetology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — KO mice with co-IP and multiple functional readouts, single lab","pmids":["24498880"],"is_preprint":false},{"year":2018,"finding":"SUR1-Kir6.2 (K(ATP)) and SUR1-TRPM4 heteromers are both upregulated in astrocytes after contusion-TBI; FRET imaging demonstrates SUR1-TRPM4 heteromers in endothelium and both SUR1-TRPM4 and SUR1-KIR6.2 heteromers in astrocytes. Antisense knockdown of KIR6.2 (unlike SUR1/TRPM4 knockdown) does not reduce hemorrhagic progression of contusion, indicating SUR1-TRPM4 (not SUR1-KIR6.2) is the primary channel mediating hemorrhagic contusion expansion.","method":"FRET imaging; antisense oligodeoxynucleotide (AS-ODN) knockdown; immunohistochemistry; contusion volume measurement","journal":"Journal of neurotrauma","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — FRET protein interaction evidence with functional AS-ODN loss-of-function, single lab with orthogonal methods","pmids":["30160201"],"is_preprint":false},{"year":2020,"finding":"Kir6.2 is palmitoylated at Cys166; palmitoylation of Kir6.2 promotes channel opening by enhancing PIP2 sensitivity without affecting surface expression. Mutagenesis of Cys166 prevents palmitoylation effects. Palmitoylation blunts regulation of K(ATP) channels by α1-adrenoreceptor stimulation. Clinical KCNJ11 variants affecting Cys166 show gain-of-function phenotypes consistent with palmitoylation mimicry.","method":"Acyl-biotin exchange assay; site-directed mutagenesis (C166); patch-clamp electrophysiology in transfected cells, INS-1 cells, and isolated cardiomyocytes; palmitate preincubation; protein thioesterase inhibition","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Moderate — acyl-biotin exchange assay with mutagenesis and electrophysiology in multiple cell types, single lab with multiple orthogonal methods","pmids":["32332165"],"is_preprint":false},{"year":2024,"finding":"CryoEM structure of open-state K(ATP) channel (Kir6.2-Q52R neonatal diabetes mutant) reveals two tandem PIP2 binding sites at the SUR1–Kir6.2 interface: a canonical site conserved among PIP2-gated Kir channels and a non-canonical site at the subunit interface. Kir6.2 pore opening is associated with a twist of the cytoplasmic domain and SUR1 N-terminal transmembrane domain rotation that widens the ATP binding pocket. Q52R stabilizes the open state via cation-π bonding with SUR1-W51. Functional studies confirm both PIP2 binding sites determine channel activity.","method":"CryoEM structure determination; functional mutagenesis; patch-clamp electrophysiology","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 / Strong — high-resolution cryoEM structure with functional mutagenesis validation, multiple orthogonal methods","pmids":["38509107"],"is_preprint":false}],"current_model":"Kir6.2 (KCNJ11) is the pore-forming subunit of the K(ATP) channel that forms hetero-octameric complexes with sulfonylurea receptor isoforms (SUR1 for pancreatic/neuronal, SUR2A for cardiac, SUR2B for smooth muscle channels); Kir6.2 directly confers ATP inhibition through its N- and C-terminal cytoplasmic domains (with key residues R50, R201, K185, and others), while PIP2 binding to a canonical site and a non-canonical SUR1-interface site promotes opening and antagonizes ATP inhibition (structurally resolved by cryoEM); channel activity is further modulated by post-translational modifications including PKA phosphorylation at Ser372 (activating), PKC phosphorylation at Ser372 (inhibitory via internalization), CaMKII phosphorylation at Thr224 (inhibitory), and palmitoylation at Cys166 (activating via enhanced PIP2 sensitivity); membrane targeting depends on ankyrin-B and βIV-spectrin scaffolds; gain-of-function mutations reduce ATP sensitivity and cause neonatal diabetes (and DEND syndrome when the open-state stabilization is severe), while loss-of-function mutations cause congenital hyperinsulinism, and the common E23K polymorphism modestly increases type 2 diabetes risk."},"narrative":{"mechanistic_narrative":"KCNJ11 encodes Kir6.2, the pore-forming subunit of the ATP-sensitive potassium (K(ATP)) channel that couples cellular metabolic state to membrane excitability across pancreatic beta-cells, neurons, and cardiomyocytes [PMID:9144288, PMID:10868950]. Kir6.2 assembles combinatorially with sulfonylurea receptor isoforms — SUR1 for the beta-cell/neuronal channel, SUR2A for the cardiac sarcolemmal channel, and SUR2B for the smooth-muscle channel — and the choice of SUR partner specifies the tissue-specific pharmacology and gating of the resulting channel [PMID:8798681, PMID:10093054, PMID:11282890]. ATP inhibition is conferred intrinsically by Kir6.2 itself, as a C-terminally truncated Kir6.2 forms ATP-sensitive channels in the absence of SUR1 [PMID:9144288]; positively charged and polar residues distributed across both the N-terminus (R50) and C-terminus (K185, R192, R201) form the nucleotide-binding/transduction surface, with the N- and C-termini cooperating to drive pore closure [PMID:9831713, PMID:12524280]. Channel opening is promoted by PIP2 binding to a defined set of N-terminal, transmembrane, and C-terminal residues that antagonizes ATP inhibition [PMID:12034765, PMID:17673911], and a cryoEM structure of an open-state channel resolves both a canonical and a non-canonical SUR1–Kir6.2 interface PIP2 site, linking pore opening to a cytoplasmic-domain twist and widening of the ATP pocket [PMID:38509107]. The Kir6.2 N-terminus and a discrete SUR1–Kir6.2 interface (SUR1-E203/Kir6.2-Q52, SUR1 residues 196–288) physically couple SUR1 drug binding to pore gating [PMID:19351728, PMID:22802363], and the N-terminus is also required for high-affinity binding of sulfonylurea-class drugs such as repaglinide [PMID:15678092]. Channel activity is further tuned by phosphorylation — PKA activates via Ser372, PKC inhibits via Ser372-dependent internalization, and CaMKII inhibits via Thr224 — and by palmitoylation at Cys166, which enhances PIP2 sensitivity [PMID:10469651, PMID:22207763, PMID:24101510, PMID:32332165]. In beta-cells, K(ATP) channels set the resting potential and gate glucose- and sulfonylurea-induced depolarization, Ca2+ entry, and insulin secretion [PMID:10868950]; in the heart, sarcolemmal Kir6.2 channels mediate responses to channel openers and contribute to ischemic-preconditioning energetic protection [PMID:11282890, PMID:12598229]. Gain-of-function KCNJ11 mutations reduce ATP sensitivity and cause permanent neonatal diabetes, with the most severe open-state-stabilizing mutations producing DEND syndrome, whereas a Kir6.2 M2-domain mutation causes persistent hyperinsulinemic hypoglycemia of infancy [PMID:8923010, PMID:15115830, PMID:15583126].","teleology":[{"year":1996,"claim":"Established that Kir6.2 is a necessary subunit of the beta-cell K(ATP) channel and that its assembly with SUR isoforms generates tissue-specific channels, framing the channel as a combinatorial heteromer.","evidence":"Genetic sequencing of a PHHI family plus functional reconstitution of Kir6.2 with SUR1 and with the novel SUR2B isoform; patch-clamp","pmids":["8923010","8798681"],"confidence":"High","gaps":["Did not resolve where on Kir6.2 ATP acts","Stoichiometry and structural arrangement of the heteromer not defined"]},{"year":1997,"claim":"Resolved the long-standing question of whether ATP inhibition resides on Kir6.2 or SUR1 by showing a C-terminally truncated Kir6.2 forms ATP-sensitive channels alone, localizing the ATP-inhibitory site to the pore subunit while SUR1 confers sulfonylurea/diazoxide/Mg-ADP responsiveness.","evidence":"Truncation mutagenesis (ΔC26) of Kir6.2 expressed in Xenopus oocytes; patch-clamp","pmids":["9144288"],"confidence":"High","gaps":["Did not identify the specific ATP-contacting residues","Mechanism of SUR1-Kir6.2 functional coupling unresolved"]},{"year":1999,"claim":"Mapped the ATP-inhibitory and coupling determinants to specific Kir6.2 regions — the N-terminus couples SUR1 drug binding to pore closure, and N- and C-terminal residues (R50, plus C-terminal sites) cooperate in ATP transduction — and identified PKA Ser372 phosphorylation as an activating modulation.","evidence":"N-terminal deletion and point mutagenesis, PKA phosphorylation assays in oocyte homogenates and intact cells, patch-clamp","pmids":["10381582","9831713","10469651"],"confidence":"High","gaps":["Atomic geometry of the ATP site not yet defined","Did not establish full set of nucleotide-contacting residues"]},{"year":2001,"claim":"Demonstrated by knockout and rescue that Kir6.2 is the obligate pore of the cardiac sarcolemmal K(ATP) channel but is dispensable in arterial smooth muscle, defining its tissue distribution in vivo.","evidence":"Kir6.2-knockout mice, gene-transfer rescue, patch-clamp and contractile assays","pmids":["11282890"],"confidence":"High","gaps":["Did not address cardiac mitochondrial K(ATP) contribution","SUR partner specificity in vivo not dissected here"]},{"year":2000,"claim":"Established physiologically that beta-cell K(ATP) channels set resting potential and are required for glucose- and sulfonylurea-coupled insulin secretion, beta-cell survival, and islet architecture.","evidence":"Dominant-negative (G132S) transgenic and Kir6.2-knockout mice; insulin secretion, electrophysiology, calcium imaging","pmids":["10868950"],"confidence":"High","gaps":["Did not define molecular basis of survival/architecture defects","Human disease relevance addressed only later"]},{"year":2003,"claim":"Defined the electrostatic chemistry of nucleotide inhibition by showing C-terminal K185 and R201 contact phosphate groups (R201 stabilizing the closed state via the alpha-phosphate), and located the C-terminal phospholipid/PIP2-interacting helix.","evidence":"Systematic site-directed mutagenesis, GFP-fragment membrane association, patch-clamp","pmids":["12524280","12034765"],"confidence":"High","gaps":["Did not provide a structural model of the nucleotide pocket","Coupling between PIP2 site and ATP site inferred functionally"]},{"year":2005,"claim":"Identified the PIP2 binding residues across N-terminus, transmembrane, and C-terminus and showed PIP2 opens the channel while reducing ATP binding, establishing PIP2 as the physiological antagonist of ATP inhibition.","evidence":"Homology modelling and docking validated by mutagenesis and patch-clamp (reported 2007; multiple residue mutants)","pmids":["17673911"],"confidence":"High","gaps":["Model-based site assignment lacked an experimental structure at the time","Number and arrangement of PIP2 sites unresolved"]},{"year":2004,"claim":"Connected Kir6.2 mechanism to human disease by showing heterozygous gain-of-function KCNJ11 mutations reduce ATP sensitivity to cause permanent neonatal diabetes (and DEND syndrome), and dissected two mechanistic classes — direct impairment of ATP binding/transduction versus indirect bias toward the open state.","evidence":"KCNJ11 patient sequencing, heterologous expression of mutant Kir6.2/SUR1, patch-clamp with kinetic analysis, in vivo secretion tests","pmids":["15115830","15583126","15864298","15962003","17021801"],"confidence":"High","gaps":["Did not establish atomic explanation for open-state stabilization until cryoEM","Genotype–phenotype severity correlation defined functionally, not structurally"]},{"year":2006,"claim":"Validated the disease mechanism in a native beta-cell context, showing inducible R201H expression collapses ATP sensitivity, abolishes metabolic channel closure, electrical activity, and insulin secretion.","evidence":"Tetracycline-inducible R201H expression in INS-1 cells; patch-clamp; insulin secretion assay","pmids":["17065345"],"confidence":"High","gaps":["Single mutation in a cell line, not in vivo human islet","Did not address neuronal DEND phenotype mechanism"]},{"year":2009,"claim":"Defined a physical SUR1–Kir6.2 coupling interface, showing Kir6.2 N-terminal residues 28–32 interact with SUR1 residues 196–288 to transmit drug binding into gating.","evidence":"Co-immunoprecipitation of fragments plus in-frame deletion mutagenesis and patch-clamp","pmids":["19351728"],"confidence":"High","gaps":["Interface mapped by deletion/co-IP, not by structure","Did not define full interface contact map"]},{"year":2012,"claim":"Pinpointed a precise SUR1-E203/Kir6.2-Q52 contact controlling ATP sensitivity, using disulfide cross-linking to lock the channel closed and proving close physical proximity at a functionally critical interface.","evidence":"Cysteine mutagenesis and disulfide cross-linking; patch-clamp in Xenopus oocytes","pmids":["22802363"],"confidence":"High","gaps":["Did not resolve full interface geometry","Relationship to PIP2 site addressed only by later cryoEM"]},{"year":2013,"claim":"Extended channel regulation to multivalent phosphorylation and scaffolding, showing βIV-spectrin targets CaMKII to phosphorylate Kir6.2-Thr224 (inhibitory), ankyrin-B controls cardiac Kir6.2 surface expression and gating, and PKC inhibits via Ser372-driven internalization.","evidence":"In vitro kinase assays, site-directed mutagenesis, co-IP, transgenic mice, patch-clamp","pmids":["24101510","20610380","22207763"],"confidence":"High","gaps":["Interplay between competing Ser372 PKA/PKC effects not fully integrated","Physiological stimuli triggering each modification incompletely defined"]},{"year":2020,"claim":"Added lipid post-translational regulation, showing palmitoylation at Cys166 promotes opening by enhancing PIP2 sensitivity and that clinical Cys166 variants behave as gain-of-function, mimicking palmitoylation.","evidence":"Acyl-biotin exchange, C166 mutagenesis, patch-clamp in multiple cell types","pmids":["32332165"],"confidence":"High","gaps":["Enzymes mediating Kir6.2 palmitoylation/depalmitoylation not identified","Dynamic regulation in vivo not established"]},{"year":2024,"claim":"Provided the structural basis for gating by solving an open-state cryoEM structure of a Kir6.2-Q52R channel, revealing tandem canonical and non-canonical PIP2 sites at the SUR1–Kir6.2 interface and a cytoplasmic-domain twist that widens the ATP pocket, with Q52R stabilizing the open state via cation-π bonding to SUR1-W51.","evidence":"CryoEM structure determination with functional mutagenesis and patch-clamp validation","pmids":["38509107"],"confidence":"High","gaps":["Closed/ATP-bound conformational transition not fully captured here","Structural basis of every disease mutation not individually resolved"]},{"year":null,"claim":"How the multiple regulatory inputs — ATP, PIP2, palmitoylation, and competing PKA/PKC/CaMKII phosphorylation — are integrated dynamically at a single channel in different tissues, and how trafficking/degradation (ubiquitin-proteasome, ankyrin/spectrin scaffolds) tunes channel density in vivo, remains incompletely defined.","evidence":"","pmids":[],"confidence":"Medium","gaps":["Quantitative model of competing modifications absent","Tissue-specific regulatory hierarchy not resolved","In vivo degradation control of channel abundance underexplored"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0005215","term_label":"transporter activity","supporting_discovery_ids":[0,7,8,27]},{"term_id":"GO:0140313","term_label":"molecular sequestering activity","supporting_discovery_ids":[0,4,10]},{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[9,20,30]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[7,8,22,23,30]},{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[27]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[5,8,25]},{"term_id":"R-HSA-382551","term_label":"Transport of small molecules","supporting_discovery_ids":[0,8]},{"term_id":"R-HSA-112316","term_label":"Neuronal System","supporting_discovery_ids":[12]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[1,12,13]},{"term_id":"R-HSA-397014","term_label":"Muscle contraction","supporting_discovery_ids":[7,11]}],"complexes":["K(ATP) channel (Kir6.2/SUR1)","Kir6.2/SUR2A cardiac K(ATP) channel","Kir6.2/SUR2B smooth-muscle K(ATP) channel","ankyrin-B/Na,K-ATPase/K(ATP) membrane complex"],"partners":["ABCC8","ABCC9","ANK2","SPTBN4","PRKACA","CAMK2D","PRKCA","PRKAA1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q14654","full_name":"ATP-sensitive inward rectifier potassium channel 11","aliases":["IKATP","Inward rectifier K(+) channel Kir6.2","Potassium channel, inwardly rectifying subfamily J member 11"],"length_aa":390,"mass_kda":43.5,"function":"Inward rectifier potassium channel that forms the pore of ATP-sensitive potassium channels (KATP), regulating potassium permeability as a function of cytoplasmic ATP and ADP concentrations in many different cells (PubMed:29286281, PubMed:34815345). Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their voltage dependence is regulated by the concentration of extracellular potassium; as external potassium is raised, the voltage range of the channel opening shifts to more positive voltages. The inward rectification is mainly due to the blockage of outward current by internal magnesium. Can be blocked by extracellular barium (By similarity). In pancreatic cells, it forms KATP channels with ABCC8/SUR1 (PubMed:29286281, PubMed:34815345). Can form cardiac and smooth muscle-type KATP channels with ABCC9","subcellular_location":"Membrane","url":"https://www.uniprot.org/uniprotkb/Q14654/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/KCNJ11","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/KCNJ11","total_profiled":1310},"omim":[{"mim_id":"618858","title":"DIABETES MELLITUS, PERMANENT NEONATAL, 4; PNDM4","url":"https://www.omim.org/entry/618858"},{"mim_id":"618857","title":"DIABETES MELLITUS, PERMANENT NEONATAL, 3; PNDM3","url":"https://www.omim.org/entry/618857"},{"mim_id":"618856","title":"DIABETES MELLITUS, PERMANENT NEONATAL, 2; PNDM2","url":"https://www.omim.org/entry/618856"},{"mim_id":"616329","title":"MATURITY-ONSET DIABETES OF THE YOUNG, TYPE 13; MODY13","url":"https://www.omim.org/entry/616329"},{"mim_id":"610582","title":"DIABETES MELLITUS, TRANSIENT NEONATAL, 3; TNDM3","url":"https://www.omim.org/entry/610582"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"skeletal muscle","ntpm":106.1},{"tissue":"tongue","ntpm":40.3}],"url":"https://www.proteinatlas.org/search/KCNJ11"},"hgnc":{"alias_symbol":["Kir6.2","BIR"],"prev_symbol":[]},"alphafold":{"accession":"Q14654","domains":[{"cath_id":"1.10.287.70","chopping":"53-173","consensus_level":"high","plddt":91.7693,"start":53,"end":173},{"cath_id":"2.60.40.1400","chopping":"178-347","consensus_level":"high","plddt":92.5286,"start":178,"end":347}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q14654","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q14654-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q14654-F1-predicted_aligned_error_v6.png","plddt_mean":83.81},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=KCNJ11","jax_strain_url":"https://www.jax.org/strain/search?query=KCNJ11"},"sequence":{"accession":"Q14654","fasta_url":"https://rest.uniprot.org/uniprotkb/Q14654.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q14654/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q14654"}},"corpus_meta":[{"pmid":"15115830","id":"PMC_15115830","title":"Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes.","date":"2004","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/15115830","citation_count":863,"is_preprint":false},{"pmid":"9144288","id":"PMC_9144288","title":"Truncation of Kir6.2 produces ATP-sensitive K+ channels in the absence of the sulphonylurea receptor.","date":"1997","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/9144288","citation_count":671,"is_preprint":false},{"pmid":"12540637","id":"PMC_12540637","title":"Large-scale association studies of variants in genes encoding the pancreatic beta-cell KATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) confirm that the KCNJ11 E23K variant is associated with type 2 diabetes.","date":"2003","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/12540637","citation_count":552,"is_preprint":false},{"pmid":"9525868","id":"PMC_9525868","title":"A single BIR domain of XIAP sufficient for inhibiting caspases.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9525868","citation_count":508,"is_preprint":false},{"pmid":"8798681","id":"PMC_8798681","title":"A novel sulfonylurea receptor forms with BIR (Kir6.2) a smooth muscle type ATP-sensitive K+ channel.","date":"1996","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8798681","citation_count":478,"is_preprint":false},{"pmid":"8923010","id":"PMC_8923010","title":"Mutation of the pancreatic islet inward rectifier Kir6.2 also leads to familial persistent hyperinsulinemic hypoglycemia of infancy.","date":"1996","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/8923010","citation_count":343,"is_preprint":false},{"pmid":"16123337","id":"PMC_16123337","title":"Activating mutations in Kir6.2 and neonatal diabetes: new clinical syndromes, new scientific insights, and new therapy.","date":"2005","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/16123337","citation_count":321,"is_preprint":false},{"pmid":"10407412","id":"PMC_10407412","title":"An exegesis of IAPs: salvation and surprises from BIR motifs.","date":"1999","source":"Trends in cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/10407412","citation_count":290,"is_preprint":false},{"pmid":"10983970","id":"PMC_10983970","title":"The survivin-like C. elegans BIR-1 protein acts with the Aurora-like kinase AIR-2 to affect chromosomes and the spindle midzone.","date":"2000","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/10983970","citation_count":218,"is_preprint":false},{"pmid":"10209096","id":"PMC_10209096","title":"Caenorhabditis elegans inhibitor of apoptosis protein (IAP) homologue BIR-1 plays a conserved role in cytokinesis.","date":"1999","source":"Current biology : CB","url":"https://pubmed.ncbi.nlm.nih.gov/10209096","citation_count":205,"is_preprint":false},{"pmid":"9867219","id":"PMC_9867219","title":"Missense mutations in the pancreatic islet beta cell inwardly rectifying K+ channel gene (KIR6.2/BIR): a meta-analysis suggests a role in the polygenic basis of Type II diabetes mellitus in Caucasians.","date":"1998","source":"Diabetologia","url":"https://pubmed.ncbi.nlm.nih.gov/9867219","citation_count":200,"is_preprint":false},{"pmid":"15583126","id":"PMC_15583126","title":"Molecular basis of Kir6.2 mutations associated with neonatal diabetes or neonatal diabetes plus neurological features.","date":"2004","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/15583126","citation_count":194,"is_preprint":false},{"pmid":"18767144","id":"PMC_18767144","title":"Update of mutations in the genes encoding the pancreatic beta-cell K(ATP) channel subunits Kir6.2 (KCNJ11) and sulfonylurea receptor 1 (ABCC8) in diabetes mellitus and hyperinsulinism.","date":"2009","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/18767144","citation_count":191,"is_preprint":false},{"pmid":"16609879","id":"PMC_16609879","title":"Mutations in KCNJ11, which encodes Kir6.2, are a common cause of diabetes diagnosed in the first 6 months of life, with the phenotype determined by genotype.","date":"2006","source":"Diabetologia","url":"https://pubmed.ncbi.nlm.nih.gov/16609879","citation_count":171,"is_preprint":false},{"pmid":"11282890","id":"PMC_11282890","title":"Functional roles of cardiac and vascular ATP-sensitive potassium channels clarified by Kir6.2-knockout mice.","date":"2001","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/11282890","citation_count":158,"is_preprint":false},{"pmid":"10469651","id":"PMC_10469651","title":"PKA-mediated phosphorylation of the human K(ATP) channel: separate roles of Kir6.2 and SUR1 subunit phosphorylation.","date":"1999","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/10469651","citation_count":148,"is_preprint":false},{"pmid":"22701567","id":"PMC_22701567","title":"Whole-exome sequencing and high throughput genotyping identified KCNJ11 as the thirteenth MODY gene.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22701567","citation_count":145,"is_preprint":false},{"pmid":"16282325","id":"PMC_16282325","title":"Distinct BIR domains of cIAP1 mediate binding to and ubiquitination of tumor necrosis factor receptor-associated factor 2 and second mitochondrial activator of caspases.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16282325","citation_count":136,"is_preprint":false},{"pmid":"32027066","id":"PMC_32027066","title":"Update of variants identified in the pancreatic β-cell KATP channel genes KCNJ11 and ABCC8 in individuals with congenital hyperinsulinism and diabetes.","date":"2020","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/32027066","citation_count":131,"is_preprint":false},{"pmid":"10868950","id":"PMC_10868950","title":"Diverse roles of K(ATP) channels learned from Kir6.2 genetically engineered mice.","date":"2000","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/10868950","citation_count":128,"is_preprint":false},{"pmid":"12598229","id":"PMC_12598229","title":"Knockout of Kir6.2 negates ischemic preconditioning-induced protection of myocardial energetics.","date":"2003","source":"American journal of physiology. Heart and circulatory physiology","url":"https://pubmed.ncbi.nlm.nih.gov/12598229","citation_count":113,"is_preprint":false},{"pmid":"11329368","id":"PMC_11329368","title":"Two kinds of BIR-containing protein - inhibitors of apoptosis, or required for mitosis.","date":"2001","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/11329368","citation_count":98,"is_preprint":false},{"pmid":"20685672","id":"PMC_20685672","title":"ABCC8 and KCNJ11 molecular spectrum of 109 patients with diazoxide-unresponsive congenital hyperinsulinism.","date":"2010","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/20685672","citation_count":92,"is_preprint":false},{"pmid":"16416420","id":"PMC_16416420","title":"Mutations in the genes encoding the pancreatic beta-cell KATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) in diabetes mellitus and hyperinsulinism.","date":"2006","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/16416420","citation_count":90,"is_preprint":false},{"pmid":"15864298","id":"PMC_15864298","title":"A gating mutation at the internal mouth of the Kir6.2 pore is associated with DEND syndrome.","date":"2005","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/15864298","citation_count":85,"is_preprint":false},{"pmid":"12707312","id":"PMC_12707312","title":"CSC-1: a subunit of the Aurora B kinase complex that binds to the survivin-like protein BIR-1 and the incenp-like protein ICP-1.","date":"2003","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/12707312","citation_count":83,"is_preprint":false},{"pmid":"26448950","id":"PMC_26448950","title":"KCNJ11: Genetic Polymorphisms and Risk of Diabetes Mellitus.","date":"2015","source":"Journal of diabetes research","url":"https://pubmed.ncbi.nlm.nih.gov/26448950","citation_count":82,"is_preprint":false},{"pmid":"10381582","id":"PMC_10381582","title":"Involvement of the n-terminus of Kir6.2 in coupling to the sulphonylurea receptor.","date":"1999","source":"The Journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/10381582","citation_count":82,"is_preprint":false},{"pmid":"9032109","id":"PMC_9032109","title":"Sequence variants in the pancreatic islet beta-cell inwardly rectifying K+ channel Kir6.2 (Bir) gene: identification and lack of role in Caucasian patients with NIDDM.","date":"1997","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/9032109","citation_count":79,"is_preprint":false},{"pmid":"30766663","id":"PMC_30766663","title":"Targeting the BIR Domains of Inhibitor of Apoptosis (IAP) Proteins in Cancer Treatment.","date":"2019","source":"Computational and structural biotechnology journal","url":"https://pubmed.ncbi.nlm.nih.gov/30766663","citation_count":73,"is_preprint":false},{"pmid":"16019717","id":"PMC_16019717","title":"Mutations in the Kir6.2 subunit of the KATP channel and permanent neonatal diabetes: new insights and new treatment.","date":"2005","source":"Annals of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/16019717","citation_count":73,"is_preprint":false},{"pmid":"18073297","id":"PMC_18073297","title":"The G53D mutation in Kir6.2 (KCNJ11) is associated with neonatal diabetes and motor dysfunction in adulthood that is improved with sulfonylurea therapy.","date":"2007","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/18073297","citation_count":69,"is_preprint":false},{"pmid":"10093054","id":"PMC_10093054","title":"Physical association between recombinant cardiac ATP-sensitive K+ channel subunits Kir6.2 and SUR2A.","date":"1999","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/10093054","citation_count":69,"is_preprint":false},{"pmid":"22385882","id":"PMC_22385882","title":"KCNJ11 gene E23K variant and therapeutic response to sulfonylureas.","date":"2011","source":"European journal of internal medicine","url":"https://pubmed.ncbi.nlm.nih.gov/22385882","citation_count":67,"is_preprint":false},{"pmid":"15579781","id":"PMC_15579781","title":"Hyperinsulinism of infancy: novel ABCC8 and KCNJ11 mutations and evidence for additional locus heterogeneity.","date":"2004","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/15579781","citation_count":66,"is_preprint":false},{"pmid":"20922570","id":"PMC_20922570","title":"Permanent neonatal diabetes due to activating mutations in ABCC8 and KCNJ11.","date":"2010","source":"Reviews in endocrine & metabolic disorders","url":"https://pubmed.ncbi.nlm.nih.gov/20922570","citation_count":65,"is_preprint":false},{"pmid":"17673911","id":"PMC_17673911","title":"Identification of the PIP2-binding site on Kir6.2 by molecular modelling and functional analysis.","date":"2007","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/17673911","citation_count":64,"is_preprint":false},{"pmid":"9143281","id":"PMC_9143281","title":"A BIR motif containing gene of African swine fever virus, 4CL, is nonessential for growth in vitro and viral virulence.","date":"1997","source":"Virology","url":"https://pubmed.ncbi.nlm.nih.gov/9143281","citation_count":62,"is_preprint":false},{"pmid":"15842514","id":"PMC_15842514","title":"Common variants in the ATP-sensitive K+ channel genes KCNJ11 (Kir6.2) and ABCC8 (SUR1) in relation to glucose intolerance: population-based studies and meta-analyses.","date":"2005","source":"Diabetic medicine : a journal of the British Diabetic Association","url":"https://pubmed.ncbi.nlm.nih.gov/15842514","citation_count":62,"is_preprint":false},{"pmid":"15565284","id":"PMC_15565284","title":"Current status of the E23K Kir6.2 polymorphism: implications for type-2 diabetes.","date":"2004","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/15565284","citation_count":56,"is_preprint":false},{"pmid":"17257281","id":"PMC_17257281","title":"Polymorphisms of KCNJ11 (Kir6.2 gene) are associated with Type 2 diabetes and hypertension in the Korean population.","date":"2007","source":"Diabetic medicine : a journal of the British Diabetic Association","url":"https://pubmed.ncbi.nlm.nih.gov/17257281","citation_count":56,"is_preprint":false},{"pmid":"15962003","id":"PMC_15962003","title":"Kir6.2 mutations causing neonatal diabetes provide new insights into Kir6.2-SUR1 interactions.","date":"2005","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/15962003","citation_count":55,"is_preprint":false},{"pmid":"12034765","id":"PMC_12034765","title":"Structural and functional determinants of conserved lipid interaction domains of inward rectifying Kir6.2 channels.","date":"2002","source":"The Journal of general physiology","url":"https://pubmed.ncbi.nlm.nih.gov/12034765","citation_count":54,"is_preprint":false},{"pmid":"15910877","id":"PMC_15910877","title":"Focus on Kir6.2: a key component of the ATP-sensitive potassium channel.","date":"2005","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/15910877","citation_count":52,"is_preprint":false},{"pmid":"17021801","id":"PMC_17021801","title":"Functional analysis of six Kir6.2 (KCNJ11) mutations causing neonatal diabetes.","date":"2006","source":"Pflugers Archiv : European journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/17021801","citation_count":52,"is_preprint":false},{"pmid":"9831713","id":"PMC_9831713","title":"Involvement of the N-terminus of Kir6.2 in the inhibition of the KATP channel by ATP.","date":"1999","source":"The Journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/9831713","citation_count":52,"is_preprint":false},{"pmid":"18664331","id":"PMC_18664331","title":"Association of KCNJ11 and ABCC8 genetic polymorphisms with response to repaglinide in Chinese diabetic patients.","date":"2008","source":"Acta pharmacologica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/18664331","citation_count":51,"is_preprint":false},{"pmid":"34119519","id":"PMC_34119519","title":"Linagliptin, a DPP-4 inhibitor, ameliorates Aβ (1-42) peptides induced neurodegeneration and brain insulin resistance (BIR) via insulin receptor substrate-1 (IRS-1) in rat model of Alzheimer's disease.","date":"2021","source":"Neuropharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/34119519","citation_count":50,"is_preprint":false},{"pmid":"20610380","id":"PMC_20610380","title":"Ankyrin-B regulates Kir6.2 membrane expression and function in heart.","date":"2010","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20610380","citation_count":49,"is_preprint":false},{"pmid":"15485395","id":"PMC_15485395","title":"The BIR domain of IAP-like protein 2 is conformationally unstable: implications for caspase inhibition.","date":"2005","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/15485395","citation_count":46,"is_preprint":false},{"pmid":"29735985","id":"PMC_29735985","title":"The SERK3 elongated allele defines a role for BIR ectodomains in brassinosteroid signalling.","date":"2018","source":"Nature plants","url":"https://pubmed.ncbi.nlm.nih.gov/29735985","citation_count":45,"is_preprint":false},{"pmid":"30160201","id":"PMC_30160201","title":"Sulfonylurea Receptor 1, Transient Receptor Potential Cation Channel Subfamily M Member 4, and KIR6.2:Role in Hemorrhagic Progression of Contusion.","date":"2018","source":"Journal of neurotrauma","url":"https://pubmed.ncbi.nlm.nih.gov/30160201","citation_count":43,"is_preprint":false},{"pmid":"17327377","id":"PMC_17327377","title":"Origin of de novo KCNJ11 mutations and risk of neonatal diabetes for subsequent siblings.","date":"2007","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/17327377","citation_count":41,"is_preprint":false},{"pmid":"14514634","id":"PMC_14514634","title":"NN414, a SUR1/Kir6.2-selective potassium channel opener, reduces blood glucose and improves glucose tolerance in the VDF Zucker rat.","date":"2003","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/14514634","citation_count":41,"is_preprint":false},{"pmid":"12524280","id":"PMC_12524280","title":"Molecular basis for Kir6.2 channel inhibition by adenine nucleotides.","date":"2003","source":"Biophysical journal","url":"https://pubmed.ncbi.nlm.nih.gov/12524280","citation_count":39,"is_preprint":false},{"pmid":"17065345","id":"PMC_17065345","title":"A Kir6.2 mutation causing neonatal diabetes impairs electrical activity and insulin secretion from INS-1 beta-cells.","date":"2006","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/17065345","citation_count":36,"is_preprint":false},{"pmid":"9703328","id":"PMC_9703328","title":"Cloning of the promoters for the beta-cell ATP-sensitive K-channel subunits Kir6.2 and SUR1.","date":"1998","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/9703328","citation_count":34,"is_preprint":false},{"pmid":"32332165","id":"PMC_32332165","title":"Palmitoylation of the KATP channel Kir6.2 subunit promotes channel opening by regulating PIP2 sensitivity.","date":"2020","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/32332165","citation_count":33,"is_preprint":false},{"pmid":"21422196","id":"PMC_21422196","title":"Characterization of ABCC8 and KCNJ11 gene mutations and phenotypes in Korean patients with congenital hyperinsulinism.","date":"2011","source":"European journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/21422196","citation_count":32,"is_preprint":false},{"pmid":"28057023","id":"PMC_28057023","title":"XIAP BIR domain suppresses miR-200a expression and subsequently promotes EGFR protein translation and anchorage-independent growth of bladder cancer cell.","date":"2017","source":"Journal of hematology & oncology","url":"https://pubmed.ncbi.nlm.nih.gov/28057023","citation_count":31,"is_preprint":false},{"pmid":"21252625","id":"PMC_21252625","title":"Threonine 48 in the BIR domain of survivin is critical to its mitotic and anti-apoptotic activities and can be phosphorylated by CK2 in vitro.","date":"2011","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/21252625","citation_count":29,"is_preprint":false},{"pmid":"10742287","id":"PMC_10742287","title":"Pharmacology of human sulphonylurea receptor SUR1 and inward rectifier K(+) channel Kir6.2 combination expressed in HEK-293 cells.","date":"2000","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/10742287","citation_count":29,"is_preprint":false},{"pmid":"22802363","id":"PMC_22802363","title":"Engineered interaction between SUR1 and Kir6.2 that enhances ATP sensitivity in KATP channels.","date":"2012","source":"The Journal of general physiology","url":"https://pubmed.ncbi.nlm.nih.gov/22802363","citation_count":28,"is_preprint":false},{"pmid":"24101510","id":"PMC_24101510","title":"βIV-Spectrin and CaMKII facilitate Kir6.2 regulation in pancreatic beta cells.","date":"2013","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/24101510","citation_count":27,"is_preprint":false},{"pmid":"15678092","id":"PMC_15678092","title":"Kir6.2-dependent high-affinity repaglinide binding to beta-cell K(ATP) channels.","date":"2005","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/15678092","citation_count":27,"is_preprint":false},{"pmid":"38509107","id":"PMC_38509107","title":"Structure of an open KATP channel reveals tandem PIP2 binding sites mediating the Kir6.2 and SUR1 regulatory interface.","date":"2024","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/38509107","citation_count":27,"is_preprint":false},{"pmid":"24710510","id":"PMC_24710510","title":"Quantitative assessment of the effect of KCNJ11 gene polymorphism on the risk of type 2 diabetes.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24710510","citation_count":27,"is_preprint":false},{"pmid":"15044189","id":"PMC_15044189","title":"Pore loop-mutated rat KIR6.1 and KIR6.2 suppress KATP current in rat cardiomyocytes.","date":"2004","source":"American journal of physiology. Heart and circulatory physiology","url":"https://pubmed.ncbi.nlm.nih.gov/15044189","citation_count":27,"is_preprint":false},{"pmid":"30377186","id":"PMC_30377186","title":"Cognitive, Neurological, and Behavioral Features in Adults With KCNJ11 Neonatal Diabetes.","date":"2018","source":"Diabetes care","url":"https://pubmed.ncbi.nlm.nih.gov/30377186","citation_count":26,"is_preprint":false},{"pmid":"27086753","id":"PMC_27086753","title":"Psychiatric morbidity in children with KCNJ11 neonatal diabetes.","date":"2016","source":"Diabetic medicine : a journal of the British Diabetic Association","url":"https://pubmed.ncbi.nlm.nih.gov/27086753","citation_count":26,"is_preprint":false},{"pmid":"22207763","id":"PMC_22207763","title":"Regulation of the ATP-sensitive potassium channel subunit, Kir6.2, by a Ca2+-dependent protein kinase C.","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22207763","citation_count":26,"is_preprint":false},{"pmid":"17894829","id":"PMC_17894829","title":"Gene-gene interactions between HNF4A and KCNJ11 in predicting Type 2 diabetes in women.","date":"2007","source":"Diabetic medicine : a journal of the British Diabetic Association","url":"https://pubmed.ncbi.nlm.nih.gov/17894829","citation_count":25,"is_preprint":false},{"pmid":"22711539","id":"PMC_22711539","title":"Role of melanoma inhibitor of apoptosis (ML-IAP) protein, a member of the baculoviral IAP repeat (BIR) domain family, in the regulation of C-RAF kinase and cell migration.","date":"2012","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22711539","citation_count":24,"is_preprint":false},{"pmid":"28587604","id":"PMC_28587604","title":"KCNJ11, ABCC8 and TCF7L2 polymorphisms and the response to sulfonylurea treatment in patients with type 2 diabetes: a bioinformatics assessment.","date":"2017","source":"BMC medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/28587604","citation_count":23,"is_preprint":false},{"pmid":"22591706","id":"PMC_22591706","title":"Association of KCNJ11 E23K gene polymorphism with hypoglycemia in sulfonylurea-treated type 2 diabetic patients.","date":"2012","source":"Diabetes research and clinical practice","url":"https://pubmed.ncbi.nlm.nih.gov/22591706","citation_count":23,"is_preprint":false},{"pmid":"30258870","id":"PMC_30258870","title":"Correlation between KCNQ1 and KCNJ11 gene polymorphisms and type 2 and post-transplant diabetes mellitus in the Asian Indian population.","date":"2015","source":"Genes & diseases","url":"https://pubmed.ncbi.nlm.nih.gov/30258870","citation_count":23,"is_preprint":false},{"pmid":"27242541","id":"PMC_27242541","title":"ATP Sensitive Potassium Channels in the Skeletal Muscle Function: Involvement of the KCNJ11(Kir6.2) Gene in the Determination of Mechanical Warner Bratzer Shear Force.","date":"2016","source":"Frontiers in physiology","url":"https://pubmed.ncbi.nlm.nih.gov/27242541","citation_count":22,"is_preprint":false},{"pmid":"16959852","id":"PMC_16959852","title":"Targeted expression of Kir6.2 in mitochondria confers protection against hypoxic stress.","date":"2006","source":"The Journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/16959852","citation_count":21,"is_preprint":false},{"pmid":"24498880","id":"PMC_24498880","title":"Kir6.2-containing ATP-sensitive K(+) channel is required for cardioprotection of resveratrol in mice.","date":"2014","source":"Cardiovascular diabetology","url":"https://pubmed.ncbi.nlm.nih.gov/24498880","citation_count":21,"is_preprint":false},{"pmid":"25625107","id":"PMC_25625107","title":"Association of KCNJ11 (E23K) gene polymorphism with susceptibility to type 2 diabetes in Iranian patients.","date":"2015","source":"Advanced biomedical research","url":"https://pubmed.ncbi.nlm.nih.gov/25625107","citation_count":21,"is_preprint":false},{"pmid":"31195986","id":"PMC_31195986","title":"Association of KCNJ11 rs5219 gene polymorphism with type 2 diabetes mellitus in a population of Syria: a case-control study.","date":"2019","source":"BMC medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/31195986","citation_count":21,"is_preprint":false},{"pmid":"17825556","id":"PMC_17825556","title":"Reduced expression of Kir6.2/SUR2A subunits explains KATP deficiency in K+-depleted rats.","date":"2007","source":"Neuromuscular disorders : NMD","url":"https://pubmed.ncbi.nlm.nih.gov/17825556","citation_count":20,"is_preprint":false},{"pmid":"15882977","id":"PMC_15882977","title":"Proteasomal degradation of Kir6.2 channel protein and its inhibition by a Na+ channel blocker aprindine.","date":"2005","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/15882977","citation_count":20,"is_preprint":false},{"pmid":"24332549","id":"PMC_24332549","title":"E23K variant in KCNJ11 gene is associated with susceptibility to type 2 diabetes in the Mauritanian population.","date":"2013","source":"Primary care diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/24332549","citation_count":20,"is_preprint":false},{"pmid":"22083559","id":"PMC_22083559","title":"Importance of the Kir6.2 N-terminus for the interaction of glibenclamide and repaglinide with the pancreatic K(ATP) channel.","date":"2011","source":"Naunyn-Schmiedeberg's archives of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/22083559","citation_count":20,"is_preprint":false},{"pmid":"36456687","id":"PMC_36456687","title":"Risk of type 2 diabetes and KCNJ11 gene polymorphisms: a nested case-control study and meta-analysis.","date":"2022","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/36456687","citation_count":19,"is_preprint":false},{"pmid":"31201216","id":"PMC_31201216","title":"Structure-Activity Relationships, Pharmacokinetics, and Pharmacodynamics of the Kir6.2/SUR1-Specific Channel Opener VU0071063.","date":"2019","source":"The Journal of pharmacology and experimental therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/31201216","citation_count":19,"is_preprint":false},{"pmid":"25955821","id":"PMC_25955821","title":"Replication of KCNJ11 (p.E23K) and ABCC8 (p.S1369A) Association in Russian Diabetes Mellitus 2 Type Cohort and Meta-Analysis.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25955821","citation_count":19,"is_preprint":false},{"pmid":"24014680","id":"PMC_24014680","title":"Kir6.2 limits Ca(2+) overload and mitochondrial oscillations of ventricular myocytes in response to metabolic stress.","date":"2013","source":"American journal of physiology. Heart and circulatory physiology","url":"https://pubmed.ncbi.nlm.nih.gov/24014680","citation_count":19,"is_preprint":false},{"pmid":"10866047","id":"PMC_10866047","title":"Sulfonylurea receptor 1 and Kir6.2 expression in the novel human insulin-secreting cell line NES2Y.","date":"2000","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/10866047","citation_count":19,"is_preprint":false},{"pmid":"17296510","id":"PMC_17296510","title":"Diabetes and hypoglycaemia in young children and mutations in the Kir6.2 subunit of the potassium channel: therapeutic consequences.","date":"2006","source":"Diabetes & metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/17296510","citation_count":18,"is_preprint":false},{"pmid":"18945825","id":"PMC_18945825","title":"ATP-sensitive K+ channels in pig urethral smooth muscle cells are heteromultimers of Kir6.1 and Kir6.2.","date":"2008","source":"American journal of physiology. Renal physiology","url":"https://pubmed.ncbi.nlm.nih.gov/18945825","citation_count":18,"is_preprint":false},{"pmid":"29564810","id":"PMC_29564810","title":"Kir6.2 Deficiency Promotes Mesencephalic Neural Precursor Cell Differentiation via Regulating miR-133b/GDNF in a Parkinson's Disease Mouse Model.","date":"2018","source":"Molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/29564810","citation_count":17,"is_preprint":false},{"pmid":"32935446","id":"PMC_32935446","title":"Continuous spectrum of glucose dysmetabolism due to the KCNJ11 gene mutation-Case reports and review of the literature.","date":"2020","source":"Journal of diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/32935446","citation_count":17,"is_preprint":false},{"pmid":"19351728","id":"PMC_19351728","title":"An in-frame deletion in Kir6.2 (KCNJ11) causing neonatal diabetes reveals a site of interaction between Kir6.2 and SUR1.","date":"2009","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/19351728","citation_count":17,"is_preprint":false},{"pmid":"9799413","id":"PMC_9799413","title":"Suppression of KATP currents by gene transfer of a dominant negative Kir6.2 construct.","date":"1998","source":"Pflugers Archiv : European journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/9799413","citation_count":16,"is_preprint":false},{"pmid":"36401380","id":"PMC_36401380","title":"Association of KCNJ11 and ABCC8 single-nucleotide polymorphisms with type 2 diabetes mellitus in a Kinh Vietnamese population.","date":"2022","source":"Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36401380","citation_count":15,"is_preprint":false},{"pmid":"18948100","id":"PMC_18948100","title":"The evolution of BIR domain and its containing proteins.","date":"2008","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/18948100","citation_count":15,"is_preprint":false},{"pmid":"30467975","id":"PMC_30467975","title":"ADIPOQ, KCNJ11 and TCF7L2 polymorphisms in type 2 diabetes in Kyrgyz population: A case-control study.","date":"2018","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30467975","citation_count":15,"is_preprint":false},{"pmid":"16797737","id":"PMC_16797737","title":"Cerebral glucose transporters expression and spatial learning in the K-ATP Kir6.2(-/-) knockout mice.","date":"2006","source":"Behavioural brain research","url":"https://pubmed.ncbi.nlm.nih.gov/16797737","citation_count":15,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":54590,"output_tokens":8549,"usd":0.146003,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":18270,"output_tokens":5507,"usd":0.114513,"stage2_stop_reason":"end_turn"},"total_usd":0.260516,"stage1_batch_id":"msgbatch_01BbTCMyrRPyhtEq6b1MdwCN","stage2_batch_id":"msgbatch_011dEed5bbxYvTAaQWKJevxu","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1997,\n      \"finding\": \"Kir6.2 is the primary subunit of the K(ATP) channel at which ATP acts to mediate channel inhibition; truncation of the C-terminus of Kir6.2 (ΔC26) produces ATP-sensitive K+ channels in the absence of SUR1, demonstrating the ATP-inhibitory site resides on Kir6.2. SUR1 is required for sensitivity to sulfonylureas, diazoxide, and activation by Mg-ADP.\",\n      \"method\": \"Truncation mutagenesis of Kir6.2 expressed in Xenopus oocytes; electrophysiology (patch-clamp)\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstitution with mutagenesis in Xenopus oocyte expression system; foundational result widely replicated\",\n      \"pmids\": [\"9144288\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Kir6.2 co-expression with SUR1 reconstitutes the beta-cell K(ATP) channel; a homozygous L147P mutation in Kir6.2 (disrupting the M2 transmembrane domain) causes familial persistent hyperinsulinemic hypoglycemia of infancy (PHHI), demonstrating Kir6.2 is a necessary subunit for normal regulated insulin release.\",\n      \"method\": \"Genetic sequencing, functional reconstitution by coexpression of Kir6.2 and SUR1\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — disease-causing mutation identified with functional reconstitution context, independently replicated across populations\",\n      \"pmids\": [\"8923010\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"A novel SUR isoform (SUR2B) co-expressed with Kir6.2 reconstitutes smooth muscle-type K(ATP) channels that are activated by diazoxide and pinacidil, establishing that tissue-specific K(ATP) channel phenotypes arise from combinatorial assembly of Kir6.2 with different SUR isoforms.\",\n      \"method\": \"Heterologous coexpression in mammalian cell line; patch-clamp electrophysiology\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstitution experiment with functional readout, replicated by multiple groups\",\n      \"pmids\": [\"8798681\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"The N-terminus of Kir6.2 is involved in coupling sulfonylurea binding at SUR1 to closure of the Kir6.2 pore; N-terminal deletions (ΔN5, ΔN9, ΔN14) increase open probability, reduce ATP sensitivity, and abolish high-affinity tolbutamide block when co-expressed with SUR1, but do not alter intrinsic Kir6.2 gating in the absence of SUR1.\",\n      \"method\": \"N-terminal deletion and site-directed mutagenesis of Kir6.2; patch-clamp in Xenopus oocytes\",\n      \"journal\": \"The Journal of physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — mutagenesis with rigorous electrophysiological controls, single lab but multiple deletion constructs\",\n      \"pmids\": [\"10381582\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"The R50 residue in the N-terminus of Kir6.2 is important for ATP inhibition; R50S/A/G mutations substantially reduce ATP sensitivity (Ki increased from 117 µM to 800 µM–3.8 mM). Combining N-terminal (R50S) and C-terminal (E179Q) mutations has additive effects, suggesting N- and C-termini cooperate to mediate channel closure by ATP.\",\n      \"method\": \"Site-directed mutagenesis; patch-clamp of excised membrane patches from Xenopus oocytes\",\n      \"journal\": \"The Journal of physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — systematic mutagenesis with quantitative functional readouts, single lab\",\n      \"pmids\": [\"9831713\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"PKA directly phosphorylates Kir6.2 at Ser372 in the C-terminus and SUR1 at Ser1571; phosphorylation of Kir6.2 at Ser372 increases channel activity, while phosphorylation of SUR1 modulates basal channel properties (burst duration, interburst interval, open probability) and surface expression. PKA stimulation via Gs-coupled receptors can phosphorylate Kir6.2 in intact cells.\",\n      \"method\": \"Site-directed mutagenesis of PKA consensus sequences; phosphorylation assays in Xenopus oocyte homogenates and intact cells; electrophysiology\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct phosphorylation assay combined with mutagenesis and electrophysiology, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"10469651\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Kir6.2 physically associates with SUR2A to form the cardiac K(ATP) channel; co-immunoprecipitation of in vitro-translated proteins demonstrated direct physical interaction. The proximal C-terminus and M2 transmembrane domain of Kir6.2 are required for assembly with SUR2A, while the distal 37 amino acids of the C-terminus are not.\",\n      \"method\": \"Co-immunoprecipitation of in vitro-translated Kir6.2 deletion mutants with SUR2A\",\n      \"journal\": \"Journal of molecular and cellular cardiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP with deletion mapping, single lab, in vitro translated proteins\",\n      \"pmids\": [\"10093054\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Kir6.2 is the pore-forming subunit mediating sarcolemmal K(ATP) channel activity in ventricular cardiomyocytes; Kir6.2-knockout mice lack electrophysiological and contractile responses to K+ channel openers (pinacidil, P-1075) in the heart. In contrast, Kir6.2 plays no role in arterial smooth muscle K(ATP) channels, where only Kir6.1 is expressed.\",\n      \"method\": \"Genetic knockout (Kir6.2-KO mice); patch-clamp electrophysiology; gene transfer rescue experiment; contractile function assays\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — knockout mice combined with gene transfer rescue and multiple functional readouts\",\n      \"pmids\": [\"11282890\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"In pancreatic beta-cells, Kir6.2 subunits form the K+ ion-permeable pore and primarily confer ATP inhibition; dominant-negative Kir6.2-G132S expression and Kir6.2 knockout mice establish that K(ATP) channels are the major determinant of beta-cell resting membrane potential, are required for both glucose- and sulfonylurea-induced membrane depolarization, Ca2+ entry, and insulin secretion, and are important for beta-cell survival and islet architecture.\",\n      \"method\": \"Transgenic dominant-negative mice (Kir6.2-G132S); Kir6.2 knockout mice; insulin secretion assays; electrophysiology; calcium imaging\",\n      \"journal\": \"Diabetes\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — two independent genetic models with multiple orthogonal phenotypic readouts\",\n      \"pmids\": [\"10868950\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"The C-terminus of Kir6.2 associates with lipid membranes via a conserved domain; systematic mutagenesis of D307–F315 identifies residues E308, I309, W311, and F315 on one face of a conserved alpha-helix as critical determinants of phospholipid (PIP2) interaction and K(ATP) channel activity.\",\n      \"method\": \"GFP-tagged fragment membrane association assay; site-directed mutagenesis; patch-clamp electrophysiology\",\n      \"journal\": \"The Journal of general physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — mutagenesis combined with membrane association assay and electrophysiology, single lab\",\n      \"pmids\": [\"12034765\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Positively charged residues K185 and R201 in the C-terminus of Kir6.2 are critical for channel inhibition by adenine nucleotides via electrostatic interaction with phosphate groups; R201 interacts with the alpha-phosphate to stabilize a closed state, while K185 interacts with the beta-phosphate in a state-independent manner. R192 (C-terminus) and R50 (N-terminus) also contribute to ATP sensitivity.\",\n      \"method\": \"Site-directed mutagenesis; patch-clamp of Xenopus oocytes\",\n      \"journal\": \"Biophysical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — systematic mutagenesis of multiple residues with quantitative electrophysiological readouts, single lab\",\n      \"pmids\": [\"12524280\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Kir6.2 knockout abolishes ischemic preconditioning-induced protection of myocardial bioenergetics; preconditioned wild-type hearts showed significantly higher ATP turnover, synthesis rate, and creatine kinase-catalyzed phosphotransfer than Kir6.2-KO hearts, demonstrating that sarcolemmal K(ATP) channels (via Kir6.2) are integral to ischemic preconditioning-induced cardiac energetic protection.\",\n      \"method\": \"Kir6.2 knockout mice; 18O-assisted 31P-NMR spectroscopy; ischemia-reperfusion protocol\",\n      \"journal\": \"American journal of physiology. Heart and circulatory physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — knockout with quantitative metabolic measurements, single lab\",\n      \"pmids\": [\"12598229\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Heterozygous activating (gain-of-function) missense mutations in KCNJ11 (Kir6.2) cause permanent neonatal diabetes by reducing ATP-inhibitory sensitivity of K(ATP) channels; the most common mutation (R201H) when co-expressed with SUR1 in Xenopus oocytes greatly reduced the ability of ATP to block mutant channels, hyperpolarizing beta-cells and preventing insulin secretion. Some mutations also cause DEND syndrome (developmental delay, epilepsy, neonatal diabetes).\",\n      \"method\": \"KCNJ11 sequencing; heterologous expression of mutant Kir6.2/SUR1 in Xenopus oocytes; patch-clamp electrophysiology; in vivo insulin secretion tests\",\n      \"journal\": \"The New England journal of medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — functional reconstitution with mutagenesis replicated across multiple mutations and labs\",\n      \"pmids\": [\"15115830\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Neonatal diabetes mutations in Kir6.2 reduce ATP inhibition by two distinct mechanisms: mutations causing diabetes alone (e.g., R201C) directly impair ATP binding/transduction, while mutations causing severe DEND syndrome (e.g., Q52R, V59G) act indirectly by biasing the channel toward the open state. Disease severity correlates with the magnitude of reduction in ATP sensitivity. The slide helix (V59) is implicated in Kir channel gating.\",\n      \"method\": \"Site-directed mutagenesis; heterologous expression in Xenopus oocytes; patch-clamp electrophysiology with kinetic analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstitution with mutagenesis and mechanistic dissection, replicated across multiple mutations\",\n      \"pmids\": [\"15583126\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"The I296L mutation at the internal mouth of the Kir6.2 pore (DEND syndrome) increases whole-cell K(ATP) currents by stabilizing the open state of the channel and possibly reducing ATP binding via allosteric effects; kinetic analysis revealed the mutation impairs ATP sensitivity indirectly, implicating this region in Kir-channel gating.\",\n      \"method\": \"Site-directed mutagenesis; expression in Xenopus oocytes; patch-clamp electrophysiology; kinetic analysis\",\n      \"journal\": \"EMBO reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — mutagenesis with detailed kinetic analysis, single lab\",\n      \"pmids\": [\"15864298\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Neonatal diabetes mutations Y330C and F333I in Kir6.2 reduce ATP inhibition and alter Kir6.2/SUR1 interactions; Y330C impairs ATP binding directly and stabilizes the open state; F333I alters ATP binding/transduction directly and dramatically enhances stimulatory MgATP effects mediated via SUR1. At least three SUR1 subunits must bind/hydrolyse MgATP to open F333I mutant channels.\",\n      \"method\": \"Site-directed mutagenesis; heterologous expression in Xenopus oocytes; patch-clamp electrophysiology\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — mutagenesis with mechanistic dissection of subunit interactions, single lab\",\n      \"pmids\": [\"15962003\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"High-affinity repaglinide binding requires both SUR1 and Kir6.2; repaglinide binds with ~150-fold higher affinity to SUR1 co-expressed with Kir6.2 compared to SUR1 alone. N-terminal deletion of Kir6.2 (ΔN14) abolishes this affinity enhancement, indicating the Kir6.2 N-terminus is required for high-affinity repaglinide binding and functional inhibition. Glibenclamide binding affinity depends primarily on SUR1.\",\n      \"method\": \"Radioligand binding assay ([3H]repaglinide, [3H]glibenclamide); N-terminal deletion of Kir6.2; patch-clamp electrophysiology\",\n      \"journal\": \"British journal of pharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — binding assay with mutagenesis and electrophysiology, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"15678092\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Six novel Kir6.2 mutations (H46Y, N48D, E227K, E229K, E292G, V252A) causing neonatal diabetes all reduce K(ATP) channel inhibition by MgATP; E227K and E229K enhance intrinsic open probability (indirectly reducing ATP sensitivity), while H46Y, N48D, E292G, and V252A likely affect ATP binding directly, as they lie near the predicted ATP-binding site. None substantially altered tolbutamide sensitivity.\",\n      \"method\": \"Heterologous expression of mutant Kir6.2/SUR1 in Xenopus oocytes; patch-clamp electrophysiology\",\n      \"journal\": \"Pflugers Archiv : European journal of physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — functional reconstitution with mutagenesis, single lab\",\n      \"pmids\": [\"17021801\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Induction of the R201H Kir6.2 mutation in INS-1 beta-cells strongly reduces K(ATP) channel ATP sensitivity (IC50 from ~20 µM to ~2 mM), prevents metabolic substrate-induced channel closure, abolishes electrical activity and insulin secretion, directly demonstrating that Kir6.2 gain-of-function mutations cause neonatal diabetes by hyperpolarizing beta-cells.\",\n      \"method\": \"Stable tetracycline-regulated expression in INS-1 cells; patch-clamp electrophysiology; insulin secretion assay\",\n      \"journal\": \"Diabetes\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — inducible expression system with electrophysiology and secretion assays in beta-cell line, single lab\",\n      \"pmids\": [\"17065345\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"The G53D Kir6.2 mutation reduces channel ATP sensitivity, causing intermediate DEND syndrome; G53D channels co-expressed with SUR1 (pancreatic/neuronal isoform) show high-affinity block by gliclazide, but G53D channels with SUR2A (skeletal muscle isoform) are insensitive to gliclazide while remaining sensitive to glibenclamide, explaining why glibenclamide but not gliclazide improved motor function in a DEND patient.\",\n      \"method\": \"Reconstitution of mutant Kir6.2/SUR1 or Kir6.2/SUR2A in Xenopus oocytes; patch-clamp electrophysiology; clinical treatment assessment\",\n      \"journal\": \"The Journal of clinical endocrinology and metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — reconstitution with two SUR isoforms plus clinical correlation, single lab\",\n      \"pmids\": [\"18073297\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"PIP2 binds to Kir6.2 at a site involving residues K39, N41, R54 (N-terminus), K67 (transmembrane domain), and R176, R177, E179, R301 (C-terminus), identified by homology modelling and validated by mutagenesis; PIP2 increases channel opening and decreases ATP binding and channel inhibition.\",\n      \"method\": \"Homology modelling; ligand docking; site-directed mutagenesis; patch-clamp electrophysiology in Xenopus oocytes\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — computational model validated by systematic mutagenesis and electrophysiology, single lab\",\n      \"pmids\": [\"17673911\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Residues 28–32 in the N-terminus of Kir6.2 physically and functionally interact with SUR1 (specifically residues 196–288 of SUR1); an in-frame deletion of residues 28–32 impairs coupling between SUR1 and Kir6.2, increases intrinsic open probability, reduces ATP sensitivity, and disrupts co-immunoprecipitation with SUR1 N-terminal fragments.\",\n      \"method\": \"Co-immunoprecipitation; heterologous expression in Xenopus oocytes; patch-clamp electrophysiology\",\n      \"journal\": \"The Journal of clinical endocrinology and metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP combined with electrophysiology and mutagenesis, single lab with two orthogonal methods\",\n      \"pmids\": [\"19351728\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Ankyrin-B directly associates with Kir6.2 in the cardiac sarcolemma; primary cardiomyocytes lacking ankyrin-B display defects in Kir6.2 protein expression, membrane expression, and K(ATP) channel function, as well as altered channel gating. Ankyrin-B forms a membrane complex with K(ATP) channels and the Na/K-ATPase.\",\n      \"method\": \"Co-immunoprecipitation; Western blot; patch-clamp electrophysiology in ankyrin-B deficient primary myocytes; subcellular fractionation\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal co-IP with functional KO phenotype and multiple readouts, single lab\",\n      \"pmids\": [\"20610380\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"A Ca2+-dependent PKC inhibits Kir6.2/SUR2B channel complexes by promoting internalization; Ser372 in the distal C-terminus of Kir6.2 is the critical phosphorylation site for this inhibitory effect, distinct from the activating PKA phosphorylation of the same residue.\",\n      \"method\": \"Site-directed mutagenesis (Ser372); biochemical internalization assay; patch-clamp electrophysiology; PKC activator/inhibitor pharmacology\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mutagenesis plus electrophysiology and biochemistry, single lab\",\n      \"pmids\": [\"22207763\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"A molecular interaction between SUR1-E203 and Kir6.2-Q52 regulates K(ATP) channel ATP sensitivity; E203K in SUR1 combined with Q52E in Kir6.2 increases ATP sensitivity ~100-fold over wild-type. Cross-linking of E203C (SUR1) and Q52C (Kir6.2) locks the channel in a closed state reversible by reducing agents, demonstrating close proximity and a functionally critical SUR1–Kir6.2 interface.\",\n      \"method\": \"Site-directed mutagenesis; disulfide cross-linking; patch-clamp electrophysiology in Xenopus oocytes\",\n      \"journal\": \"The Journal of general physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — chemical cross-linking plus mutagenesis with quantitative electrophysiology, single lab with orthogonal methods\",\n      \"pmids\": [\"22802363\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"βIV-spectrin serves as a scaffold that targets CaMKII to pancreatic islet beta-cells; CaMKII directly phosphorylates Kir6.2 at Thr224, inhibiting K(ATP) channel function and consistent with aberrant insulin regulation. βIV-spectrin mutant mice lacking CaMKII-binding motifs show selective loss of CaMKIIδ and aberrant Kir6.2 phosphorylation.\",\n      \"method\": \"Co-immunoprecipitation; site-directed mutagenesis (T224); patch-clamp electrophysiology; transgenic mice; in vitro kinase assay\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro kinase assay with mutagenesis, electrophysiology, and in vivo transgenic validation, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"24101510\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Kir6.2 channel protein is degraded via the ubiquitin-proteasome pathway; Kir6.2 has a short half-life (~1.9 h) in COS cells. Proteasome inhibitors (MG132, ALLN, lactacystin) prolong Kir6.2 half-life and increase ubiquitinated Kir6.2, augmenting K(ATP) currents. The Na+ channel blocker aprindine inhibits 20S proteasome activity and similarly stabilizes Kir6.2.\",\n      \"method\": \"Pulse-chase/half-life analysis; proteasome inhibitors; ubiquitination assay; patch-clamp electrophysiology in COS cells and neonatal cardiomyocytes\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple proteasome inhibitors with ubiquitination assay and electrophysiology, single lab\",\n      \"pmids\": [\"15882977\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Targeted expression of Kir6.2 in mitochondria increases mitochondrial K+ influx, confers protection against hypoxic stress, and attenuates mitochondrial Ca2+ accumulation; an inactive Kir6.2 mutant abolishes this protection, demonstrating that K+ conductance through Kir6.2 in the inner mitochondrial membrane directly protects against hypoxic injury.\",\n      \"method\": \"Mitochondria-targeted Kir6.2 expression (pCMV/mito/GFP vector); colocalization studies; K+-sensitive fluorescent dye (PBFI AM); mitochondrial Ca2+ imaging (rhod-2); LDH release assay\",\n      \"journal\": \"The Journal of physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — targeted expression with inactive mutant control and multiple functional readouts, single lab\",\n      \"pmids\": [\"16959852\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Kir6.2-containing K(ATP) channels mediate the cardioprotective effects of resveratrol; resveratrol enhances AMPK phosphorylation and promotes physical association of AMPK with Kir6.2. Kir6.2 knockout abolishes cardioprotection by resveratrol in vivo and in vitro. AMPK activator cardioprotection is also lost in Kir6.2 KO, placing Kir6.2 downstream of AMPK in the cardioprotective signaling pathway.\",\n      \"method\": \"Kir6.2 knockout mice; ischemia/reperfusion injury; co-immunoprecipitation (AMPK–Kir6.2); infarct size measurement; neonatal cardiomyocyte assays\",\n      \"journal\": \"Cardiovascular diabetology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KO mice with co-IP and multiple functional readouts, single lab\",\n      \"pmids\": [\"24498880\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"SUR1-Kir6.2 (K(ATP)) and SUR1-TRPM4 heteromers are both upregulated in astrocytes after contusion-TBI; FRET imaging demonstrates SUR1-TRPM4 heteromers in endothelium and both SUR1-TRPM4 and SUR1-KIR6.2 heteromers in astrocytes. Antisense knockdown of KIR6.2 (unlike SUR1/TRPM4 knockdown) does not reduce hemorrhagic progression of contusion, indicating SUR1-TRPM4 (not SUR1-KIR6.2) is the primary channel mediating hemorrhagic contusion expansion.\",\n      \"method\": \"FRET imaging; antisense oligodeoxynucleotide (AS-ODN) knockdown; immunohistochemistry; contusion volume measurement\",\n      \"journal\": \"Journal of neurotrauma\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — FRET protein interaction evidence with functional AS-ODN loss-of-function, single lab with orthogonal methods\",\n      \"pmids\": [\"30160201\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Kir6.2 is palmitoylated at Cys166; palmitoylation of Kir6.2 promotes channel opening by enhancing PIP2 sensitivity without affecting surface expression. Mutagenesis of Cys166 prevents palmitoylation effects. Palmitoylation blunts regulation of K(ATP) channels by α1-adrenoreceptor stimulation. Clinical KCNJ11 variants affecting Cys166 show gain-of-function phenotypes consistent with palmitoylation mimicry.\",\n      \"method\": \"Acyl-biotin exchange assay; site-directed mutagenesis (C166); patch-clamp electrophysiology in transfected cells, INS-1 cells, and isolated cardiomyocytes; palmitate preincubation; protein thioesterase inhibition\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — acyl-biotin exchange assay with mutagenesis and electrophysiology in multiple cell types, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"32332165\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"CryoEM structure of open-state K(ATP) channel (Kir6.2-Q52R neonatal diabetes mutant) reveals two tandem PIP2 binding sites at the SUR1–Kir6.2 interface: a canonical site conserved among PIP2-gated Kir channels and a non-canonical site at the subunit interface. Kir6.2 pore opening is associated with a twist of the cytoplasmic domain and SUR1 N-terminal transmembrane domain rotation that widens the ATP binding pocket. Q52R stabilizes the open state via cation-π bonding with SUR1-W51. Functional studies confirm both PIP2 binding sites determine channel activity.\",\n      \"method\": \"CryoEM structure determination; functional mutagenesis; patch-clamp electrophysiology\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — high-resolution cryoEM structure with functional mutagenesis validation, multiple orthogonal methods\",\n      \"pmids\": [\"38509107\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"Kir6.2 (KCNJ11) is the pore-forming subunit of the K(ATP) channel that forms hetero-octameric complexes with sulfonylurea receptor isoforms (SUR1 for pancreatic/neuronal, SUR2A for cardiac, SUR2B for smooth muscle channels); Kir6.2 directly confers ATP inhibition through its N- and C-terminal cytoplasmic domains (with key residues R50, R201, K185, and others), while PIP2 binding to a canonical site and a non-canonical SUR1-interface site promotes opening and antagonizes ATP inhibition (structurally resolved by cryoEM); channel activity is further modulated by post-translational modifications including PKA phosphorylation at Ser372 (activating), PKC phosphorylation at Ser372 (inhibitory via internalization), CaMKII phosphorylation at Thr224 (inhibitory), and palmitoylation at Cys166 (activating via enhanced PIP2 sensitivity); membrane targeting depends on ankyrin-B and βIV-spectrin scaffolds; gain-of-function mutations reduce ATP sensitivity and cause neonatal diabetes (and DEND syndrome when the open-state stabilization is severe), while loss-of-function mutations cause congenital hyperinsulinism, and the common E23K polymorphism modestly increases type 2 diabetes risk.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"KCNJ11 encodes Kir6.2, the pore-forming subunit of the ATP-sensitive potassium (K(ATP)) channel that couples cellular metabolic state to membrane excitability across pancreatic beta-cells, neurons, and cardiomyocytes [#0, #8]. Kir6.2 assembles combinatorially with sulfonylurea receptor isoforms — SUR1 for the beta-cell/neuronal channel, SUR2A for the cardiac sarcolemmal channel, and SUR2B for the smooth-muscle channel — and the choice of SUR partner specifies the tissue-specific pharmacology and gating of the resulting channel [#2, #6, #7]. ATP inhibition is conferred intrinsically by Kir6.2 itself, as a C-terminally truncated Kir6.2 forms ATP-sensitive channels in the absence of SUR1 [#0]; positively charged and polar residues distributed across both the N-terminus (R50) and C-terminus (K185, R192, R201) form the nucleotide-binding/transduction surface, with the N- and C-termini cooperating to drive pore closure [#4, #10]. Channel opening is promoted by PIP2 binding to a defined set of N-terminal, transmembrane, and C-terminal residues that antagonizes ATP inhibition [#9, #20], and a cryoEM structure of an open-state channel resolves both a canonical and a non-canonical SUR1–Kir6.2 interface PIP2 site, linking pore opening to a cytoplasmic-domain twist and widening of the ATP pocket [#31]. The Kir6.2 N-terminus and a discrete SUR1–Kir6.2 interface (SUR1-E203/Kir6.2-Q52, SUR1 residues 196–288) physically couple SUR1 drug binding to pore gating [#21, #24], and the N-terminus is also required for high-affinity binding of sulfonylurea-class drugs such as repaglinide [#16]. Channel activity is further tuned by phosphorylation — PKA activates via Ser372, PKC inhibits via Ser372-dependent internalization, and CaMKII inhibits via Thr224 — and by palmitoylation at Cys166, which enhances PIP2 sensitivity [#5, #23, #25, #30]. In beta-cells, K(ATP) channels set the resting potential and gate glucose- and sulfonylurea-induced depolarization, Ca2+ entry, and insulin secretion [#8]; in the heart, sarcolemmal Kir6.2 channels mediate responses to channel openers and contribute to ischemic-preconditioning energetic protection [#7, #11]. Gain-of-function KCNJ11 mutations reduce ATP sensitivity and cause permanent neonatal diabetes, with the most severe open-state-stabilizing mutations producing DEND syndrome, whereas a Kir6.2 M2-domain mutation causes persistent hyperinsulinemic hypoglycemia of infancy [#1, #12, #13].\",\n  \"teleology\": [\n    {\n      \"year\": 1996,\n      \"claim\": \"Established that Kir6.2 is a necessary subunit of the beta-cell K(ATP) channel and that its assembly with SUR isoforms generates tissue-specific channels, framing the channel as a combinatorial heteromer.\",\n      \"evidence\": \"Genetic sequencing of a PHHI family plus functional reconstitution of Kir6.2 with SUR1 and with the novel SUR2B isoform; patch-clamp\",\n      \"pmids\": [\"8923010\", \"8798681\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve where on Kir6.2 ATP acts\", \"Stoichiometry and structural arrangement of the heteromer not defined\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Resolved the long-standing question of whether ATP inhibition resides on Kir6.2 or SUR1 by showing a C-terminally truncated Kir6.2 forms ATP-sensitive channels alone, localizing the ATP-inhibitory site to the pore subunit while SUR1 confers sulfonylurea/diazoxide/Mg-ADP responsiveness.\",\n      \"evidence\": \"Truncation mutagenesis (ΔC26) of Kir6.2 expressed in Xenopus oocytes; patch-clamp\",\n      \"pmids\": [\"9144288\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not identify the specific ATP-contacting residues\", \"Mechanism of SUR1-Kir6.2 functional coupling unresolved\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Mapped the ATP-inhibitory and coupling determinants to specific Kir6.2 regions — the N-terminus couples SUR1 drug binding to pore closure, and N- and C-terminal residues (R50, plus C-terminal sites) cooperate in ATP transduction — and identified PKA Ser372 phosphorylation as an activating modulation.\",\n      \"evidence\": \"N-terminal deletion and point mutagenesis, PKA phosphorylation assays in oocyte homogenates and intact cells, patch-clamp\",\n      \"pmids\": [\"10381582\", \"9831713\", \"10469651\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Atomic geometry of the ATP site not yet defined\", \"Did not establish full set of nucleotide-contacting residues\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Demonstrated by knockout and rescue that Kir6.2 is the obligate pore of the cardiac sarcolemmal K(ATP) channel but is dispensable in arterial smooth muscle, defining its tissue distribution in vivo.\",\n      \"evidence\": \"Kir6.2-knockout mice, gene-transfer rescue, patch-clamp and contractile assays\",\n      \"pmids\": [\"11282890\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not address cardiac mitochondrial K(ATP) contribution\", \"SUR partner specificity in vivo not dissected here\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Established physiologically that beta-cell K(ATP) channels set resting potential and are required for glucose- and sulfonylurea-coupled insulin secretion, beta-cell survival, and islet architecture.\",\n      \"evidence\": \"Dominant-negative (G132S) transgenic and Kir6.2-knockout mice; insulin secretion, electrophysiology, calcium imaging\",\n      \"pmids\": [\"10868950\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define molecular basis of survival/architecture defects\", \"Human disease relevance addressed only later\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Defined the electrostatic chemistry of nucleotide inhibition by showing C-terminal K185 and R201 contact phosphate groups (R201 stabilizing the closed state via the alpha-phosphate), and located the C-terminal phospholipid/PIP2-interacting helix.\",\n      \"evidence\": \"Systematic site-directed mutagenesis, GFP-fragment membrane association, patch-clamp\",\n      \"pmids\": [\"12524280\", \"12034765\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not provide a structural model of the nucleotide pocket\", \"Coupling between PIP2 site and ATP site inferred functionally\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Identified the PIP2 binding residues across N-terminus, transmembrane, and C-terminus and showed PIP2 opens the channel while reducing ATP binding, establishing PIP2 as the physiological antagonist of ATP inhibition.\",\n      \"evidence\": \"Homology modelling and docking validated by mutagenesis and patch-clamp (reported 2007; multiple residue mutants)\",\n      \"pmids\": [\"17673911\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Model-based site assignment lacked an experimental structure at the time\", \"Number and arrangement of PIP2 sites unresolved\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Connected Kir6.2 mechanism to human disease by showing heterozygous gain-of-function KCNJ11 mutations reduce ATP sensitivity to cause permanent neonatal diabetes (and DEND syndrome), and dissected two mechanistic classes — direct impairment of ATP binding/transduction versus indirect bias toward the open state.\",\n      \"evidence\": \"KCNJ11 patient sequencing, heterologous expression of mutant Kir6.2/SUR1, patch-clamp with kinetic analysis, in vivo secretion tests\",\n      \"pmids\": [\"15115830\", \"15583126\", \"15864298\", \"15962003\", \"17021801\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not establish atomic explanation for open-state stabilization until cryoEM\", \"Genotype–phenotype severity correlation defined functionally, not structurally\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Validated the disease mechanism in a native beta-cell context, showing inducible R201H expression collapses ATP sensitivity, abolishes metabolic channel closure, electrical activity, and insulin secretion.\",\n      \"evidence\": \"Tetracycline-inducible R201H expression in INS-1 cells; patch-clamp; insulin secretion assay\",\n      \"pmids\": [\"17065345\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Single mutation in a cell line, not in vivo human islet\", \"Did not address neuronal DEND phenotype mechanism\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Defined a physical SUR1–Kir6.2 coupling interface, showing Kir6.2 N-terminal residues 28–32 interact with SUR1 residues 196–288 to transmit drug binding into gating.\",\n      \"evidence\": \"Co-immunoprecipitation of fragments plus in-frame deletion mutagenesis and patch-clamp\",\n      \"pmids\": [\"19351728\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Interface mapped by deletion/co-IP, not by structure\", \"Did not define full interface contact map\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Pinpointed a precise SUR1-E203/Kir6.2-Q52 contact controlling ATP sensitivity, using disulfide cross-linking to lock the channel closed and proving close physical proximity at a functionally critical interface.\",\n      \"evidence\": \"Cysteine mutagenesis and disulfide cross-linking; patch-clamp in Xenopus oocytes\",\n      \"pmids\": [\"22802363\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve full interface geometry\", \"Relationship to PIP2 site addressed only by later cryoEM\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Extended channel regulation to multivalent phosphorylation and scaffolding, showing βIV-spectrin targets CaMKII to phosphorylate Kir6.2-Thr224 (inhibitory), ankyrin-B controls cardiac Kir6.2 surface expression and gating, and PKC inhibits via Ser372-driven internalization.\",\n      \"evidence\": \"In vitro kinase assays, site-directed mutagenesis, co-IP, transgenic mice, patch-clamp\",\n      \"pmids\": [\"24101510\", \"20610380\", \"22207763\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Interplay between competing Ser372 PKA/PKC effects not fully integrated\", \"Physiological stimuli triggering each modification incompletely defined\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Added lipid post-translational regulation, showing palmitoylation at Cys166 promotes opening by enhancing PIP2 sensitivity and that clinical Cys166 variants behave as gain-of-function, mimicking palmitoylation.\",\n      \"evidence\": \"Acyl-biotin exchange, C166 mutagenesis, patch-clamp in multiple cell types\",\n      \"pmids\": [\"32332165\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Enzymes mediating Kir6.2 palmitoylation/depalmitoylation not identified\", \"Dynamic regulation in vivo not established\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Provided the structural basis for gating by solving an open-state cryoEM structure of a Kir6.2-Q52R channel, revealing tandem canonical and non-canonical PIP2 sites at the SUR1–Kir6.2 interface and a cytoplasmic-domain twist that widens the ATP pocket, with Q52R stabilizing the open state via cation-π bonding to SUR1-W51.\",\n      \"evidence\": \"CryoEM structure determination with functional mutagenesis and patch-clamp validation\",\n      \"pmids\": [\"38509107\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Closed/ATP-bound conformational transition not fully captured here\", \"Structural basis of every disease mutation not individually resolved\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the multiple regulatory inputs — ATP, PIP2, palmitoylation, and competing PKA/PKC/CaMKII phosphorylation — are integrated dynamically at a single channel in different tissues, and how trafficking/degradation (ubiquitin-proteasome, ankyrin/spectrin scaffolds) tunes channel density in vivo, remains incompletely defined.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Quantitative model of competing modifications absent\", \"Tissue-specific regulatory hierarchy not resolved\", \"In vivo degradation control of channel abundance underexplored\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0005215\", \"supporting_discovery_ids\": [0, 7, 8, 27]},\n      {\"term_id\": \"GO:0005267\", \"supporting_discovery_ids\": [0, 8]},\n      {\"term_id\": \"GO:0140313\", \"supporting_discovery_ids\": [0, 4, 10]},\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [9, 20, 30]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": []}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [7, 8, 22, 23, 30]},\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [27]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [5, 8, 25]},\n      {\"term_id\": \"R-HSA-382551\", \"supporting_discovery_ids\": [0, 8]},\n      {\"term_id\": \"R-HSA-112316\", \"supporting_discovery_ids\": [12]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [1, 12, 13]},\n      {\"term_id\": \"R-HSA-397014\", \"supporting_discovery_ids\": [7, 11]}\n    ],\n    \"complexes\": [\n      \"K(ATP) channel (Kir6.2/SUR1)\",\n      \"Kir6.2/SUR2A cardiac K(ATP) channel\",\n      \"Kir6.2/SUR2B smooth-muscle K(ATP) channel\",\n      \"ankyrin-B/Na,K-ATPase/K(ATP) membrane complex\"\n    ],\n    \"partners\": [\n      \"ABCC8\",\n      \"ABCC9\",\n      \"ANK2\",\n      \"SPTBN4\",\n      \"PRKACA\",\n      \"CAMK2D\",\n      \"PRKCA\",\n      \"PRKAA1\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}